Silexion Therapeutics Reports $6M Cash, Advances Pancreatic Cancer Drug to Phase 2/3 Trial
Summary
Silexion Therapeutics reported its fourth quarter and full year 2025 financial results, ending the year with approximately $6.0 million in cash and cash equivalents. While the company highlighted strengthening its financial position and regaining Nasdaq compliance, this cash balance provides a limited runway for a clinical-stage biotech, especially given its market capitalization. Concurrently, Silexion provided a significant business update, detailing positive preclinical findings for SIL204 across multiple KRAS mutations and cancer types, completion of toxicology studies, and submission of a Phase 2/3 clinical trial application in Israel for locally advanced pancreatic cancer. The company anticipates initiating the Phase 2/3 trial in Q2 2026. This update presents a mixed picture, with promising clinical progress balanced against a tight financial position that will likely necessitate further capital raises.
At the time of this announcement, SLXN was trading at $1.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $1.42 to $22.36. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.